High-yield strain is designed to accelerate production of human growth hormone.

Dowpharma  licensed its Pfenex Expression Technology™ to India-based Biovel Life Sciences. The agreement grants Biovel rights to employ the Pseudomonas fluorescense-based technology for the production of human growth hormone (HGH), a biosimilar product. 


Dowpharma says it has already developed a high-yield production strain and process for the production of HGH and will prepare and transfer to Biovel a research cell bank and the production process. The agreement provides for an upfront technology access fee, maintenance and milestone fees, as well as royalties on product sales.

Previous articlePharmacovigilance Impacts Drug Safety
Next articleSartorius and Thermo Fisher Scientific Sign Supply Agreement on TC Tech Products